ARCA biopharma, Inc. (NASDAQ:ABIO) Drops -9.71% in a week: What’s Hurting the Stock?

In last trading session, ARCA biopharma, Inc. (NASDAQ:ABIO) saw 331,181 shares changing hands with its beta currently measuring 2.83. Company’s recent per share price level of $4 trading at -$0.08 or -1.96% at ring of the bell on the day assigns it a market valuation of $37.29 Million. That closing price of ABIO’s stock is at a discount of -450% from its 52-week high price of $22 and is indicating a premium of 44.75% from its 52-week low price of $2.21. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 364.61 Million shares which gives us an average trading volume of 539.57 Million if we extend that period to 3-months.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

For ARCA biopharma, Inc. (ABIO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 0. Splitting up the data highlights that, out of 1 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 1 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0 in the current quarter.

In the face of being in the red today for losing -1.96%, in the last five days ABIO remained trading in the green while hitting it’s week-highest on Monday, Dec 14 when the stock touched $4.50-1 price level, adding 11.11% to its value on the day. ARCA biopharma, Inc.’s shares saw a change of -29.96% in year-to-date performance and have moved -9.71% in past 5-day. ARCA biopharma, Inc. (NASDAQ:ABIO) showed a performance of 2.56% in past 30-days. Number of shares sold short was 49.82 Million shares which calculate 0.09 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $7 to the stock, which implies a rise of 75% to its current value. Analysts have been projecting $7 as a low price target for the stock while placing it at a high target of $7. It follows that stock’s current price would jump +75% in reaching the projected high whereas dropping to the targeted low would mean a loss of 75% for stock’s current value.

ARCA biopharma, Inc. (ABIO) estimates and forecasts

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 41.3% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 59.8% while estimates for its earnings growth in next 5 years are of 0%

ARCA biopharma, Inc. (NASDAQ:ABIO)’s Major holders

Insiders are in possession of 0.29% of company’s total shares while institution are holding 8.46% percent of that, with stock having share float percentage of 8.48%. Investors also watch the number of corporate investors in a company very closely, which is 23 institutions for ARCA biopharma, Inc. that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at ABIO for having 287.26 Thousand shares of worth $1.27 Million. And as of September 29, 2020, it was holding 3.08% of the company’s outstanding shares.

The second largest institutional holder is Renaissance Technologies, LLC, which was holding about 38.31 Thousand shares on September 29, 2020. The number of shares represents firm’s hold over 0.41% of outstanding shares, having a total worth of $169.33 Thousand.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

On the other hand, Tekla Life Sciences Investors and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of September 29, 2020, the former fund manager was holding 32461 shares of worth $143.48 Thousand or 0.35% of the total outstanding shares. The later fund manager was in possession of 5.6 Thousand shares on September 29, 2020, making its stake of worth around $24.77 Thousand in the company or a holder of 0.06% of company’s stock.


This Secret NYSE Telecom Trading at $1.36 gets $35.00 Price Target by 2 Analyst!

There is a secret stock that is LOADED with opportunity for savvy investors to make a fortune!

Get all the details here >>

Sponsored


Latest posts